KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Gains from Investment Securities: 2009-2025

Historic Gains from Investment Securities for Charles River Laboratories International (CRL) over the last 16 years, with Sep 2025 value amounting to -$1.0 million.

  • Charles River Laboratories International's Gains from Investment Securities rose 67.55% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.7 million, marking a year-over-year decrease of 8210.56%. This contributed to the annual value of -$33.3 million for FY2024, which is 1549.48% down from last year.
  • According to the latest figures from Q3 2025, Charles River Laboratories International's Gains from Investment Securities is -$1.0 million, which was down 170.99% from $1.5 million recorded in Q2 2025.
  • Charles River Laboratories International's 5-year Gains from Investment Securities high stood at $15.5 million for Q4 2022, and its period low was -$24.4 million during Q4 2024.
  • For the 3-year period, Charles River Laboratories International's Gains from Investment Securities averaged around -$3.1 million, with its median value being -$1.8 million (2023).
  • Over the last 5 years, Charles River Laboratories International's Gains from Investment Securities had its largest YoY gain of 164.55% in 2022, and its largest YoY loss of 15,729.31% in 2022.
  • Over the past 5 years, Charles River Laboratories International's Gains from Investment Securities (Quarterly) stood at -$23.9 million in 2021, then soared by 164.55% to $15.5 million in 2022, then plummeted by 40.21% to $9.2 million in 2023, then tumbled by 363.51% to -$24.4 million in 2024, then surged by 67.55% to -$1.0 million in 2025.
  • Its last three reported values are -$1.0 million in Q3 2025, $1.5 million for Q2 2025, and -$3.7 million during Q1 2025.